Combined Shareholders’ Meeting of 31 May 2023

Back

Combined Shareholders’ Meeting of 31 May 2023

- 21 April 2023 - 1 mins read

Please download the associated documents for more information.

 

Voting Result

Voting form

Participate in the Shareholders’ Meeting

2022 Universal registration document

Report of the Board of Directors on the draft resolutions

Preliminary notice to the Meeting published at the BALO on 21 April 2023 – French version

Preliminary notice to the Meeting published at the BALO on 21 April 2023 – Translation for information

Documents availability – 2023 Ipsen Combined Shareholder’s Meeting

Statutory Auditors Report – 2022 Financial Statements

Statutory Auditors Report – 2022 Consolidated Financial Statements

Statutory Auditors’ special report on regulated agreements

Statutory Audit Report – resolutions 2023 CSM (in French)

Total number of voting rights and shares as of 21 April 2023

Convening Notice to the Meeting published at the BALO on 12 May 2023 – French version

Convening Notice to the Meeting published at the BALO on 12 May 2023 – Translation for information

 

Webcast Replay of Combined Shareholders’ Meeting of 31 May 2023

Related Press Releases

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
24 April 2024 7 mins read

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
22 April 2024 5 mins read

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen publishes its 2023 Universal Registration Document
17 April 2024 4 mins read

Ipsen publishes its 2023 Universal Registration Document
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
08 April 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
02 April 2024 7 mins read

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
07 March 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
15 February 2024 1 mins read

Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
08 February 2024 8 mins read

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
06 February 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital